Neuropsychiatric Symptoms in Parkinson’s Disease Patients

Year 2023, Volume: 18 Issue: 3, 105 - 109, 20.11.2023

Tuğba Kaya Buket Tuğan Yıldız

https://doi.org/10.17517/ksutfd.1214193

Abstract

Many physical, cognitive and psychological symptoms can be seen in neurological diseases. Parkinson's disease (PD) is a neurological disorder arising from the degeneration of neurons, is characterized by motor and non-motor symptoms. Along with motor symptoms, psychiatric symptoms that are included in non-motor symptoms can also be seen in PD. PD symptoms, genetic predisposition, side effects of pharmacological treatments, psychosocial factors; can cause psychiatric conditions such as anxiety, depression, impulse control disorder, and psychosis. It has been determined that the most common psychiatric disorder in PD is depression, followed by anxiety. Although the presence of psychiatric comorbidities in PD is high, it is often overlooked by clinicians during the diagnosis and treatment process. These factors should be taken into account in the diagnosis process and treatment strategies of Parkinson's patients should be structured in a multifactorial manner.

Keywords

Parkinson’s Disease, Neuropsychiatric symptoms, Anxiety, Depression, Impulse control disorder, Psychosis

Parkinson Hastalarında Nöropsikiyatrik Semptomlar

Abstract

Nörolojik hastalıklarda birçok fiziksel, bilişsel ve ruhsal belirtiler kendini gösterebilmektedir. Parkinson hastalığı (PH) nöronların dejenerasyonundan kaynaklanan, motor ve non-motor semptomlar ile karakterize olan nörolojik bir rahatsızlıktır. PH’da da motor semptomlarla beraber, non-motor semptomlar içerisine dahil olan psikiyatrik belirtiler görülebilmektedir. PH semptomları, genetik yatkınlık, uygulanan farmakolojik tedavilerin yan etkileri, psikososyal faktörler; anksiyete, depresyon, dürtü kontrol bozukluğu, psikoz gibi psikiyatrik durumların ortaya çıkmasına neden olabilmektedir. PH’de en sık görülen psikiyatrik bozukluğun depresyon olduğu, onu takip eden psikiyatrik bozukluğun ise anksiyete olduğu saptanmıştır. PH’de psikiyatrik komorbitelerin varlığı yüksek oranda olmasına rağmen, tanı ve tedavi sürecinde çoğunlukla klinisyenlerin gözünden kaçmaktadır. Tanı sürecinde bu faktörler dikkate alınmalı ve Parkinson Hastalarının tedavi stratejileri multifaktöriyel bir şekilde yapılandırılmalıdır.

Keywords

Parkinson hastalığı, Nöropsikiyatrik semptomlar, Anksiyete, Depresyon, İmpuls kontrol bozukluğu, Psikoz

References

• de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol. 2006;5(6):525-35.
• Baldereschi M, Di Carlo A, Rocca WA, Vanni P, Maggi S, Perissinotto E, et al. Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology. 2000 14;55(9):1358-1463.
• Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol. 2003;157(11):1015-1022.
• Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, Lees AJ. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry. 2000;68(4):423-428.
• Martinez-Martin P. Nonmotor symptoms and health-related quality of life in early Parkinson's disease. Mov Disord. 2014;29(2):166-168.
• Postuma RB, Aarsland D, Barone P, Burn DJ, Hawkes CH, Oertel W, et al. Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease. Mov Disord. 2012;27(5):617-626.
• Ertan S, Benbir G. Dopamine Dysregulation Syndrome and other psychiatric problems in Parkinson’s Disease: Diagnosis and Treatment. Turk J Neurol. 2011;17(2): 65-75
• Bearn J, Evans A, Kelleher M, Turner K, Lees A. Recognition of a dopamine replacement therapy dependence syndrome in Parkinson's disease: a pilot study. Drug Alcohol Depend. 2004;76(3):305-310.
• Reiff J, Jost WH. Drug-induced impulse control disorders in Parkinson’s disease. J Neurol. 2011;258:S323-327.
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.
• Andrade L, Caraveo-Anduaga JJ, Berglund P, Bijl RV, De Graaf R, Vollebergh W, et al. The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. Int J Methods Psychiatr Res. 2003;12(1):3-21.
• Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. The Lancet. 2007;370(9590):851-858.
• Slaughter JR, Slaughter KA, Nichols D, Holmes SE, Martens MP. Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 2001;13(2):187-196.
• Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord. 2008;23(2):183-189
• Ishihara L, Brayne C. A systematic review of depression and mental illness preceding Parkinson's disease. Acta Neurol Scand. 2006;113(4):211-220. doi:10.1111/j.1600-0404.2006.00579.x
• McDonald WM, Richard IH, DeLong MR. Prevalence, etiology, and treatment of depression in Parkinson’s disease. Biological Psychiatry. 2003; 54(3):363-375.
• Marsh L. Depression and Parkinson's disease: current knowledge. Curr Neurol Neurosci Rep. 2013;13(12):409.
• Paulson HL, Stern MB. Clinical manifestations of Parkinson’s disease. Ed: Watts RL, Koller WC. Movement Disorders: Neurologic Principles and Practice. Chap:14.pp.233-245. McGraw-Hill, New York, 2nd ed, 2004.
• Shulman LM, Taback RL, Rabinstein AA, Weiner WJ, et al. "Non-recognition of depression and other non-motor symptoms in Parkinson's disease." Parkinsonism & related disorders 8.3 (2002):193-197.
• Pontone GM, Williams JR, Anderson KE, Chase G, Goldstein SA, Grill S, et al. Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson's disease. Mov Disord. 2009;24(9):1333-1338.
• Dissanayaka NN, White E, O'Sullivan JD, Marsh R, Pachana NA, Byrne GJ. The clinical spectrum of anxiety in Parkinson's disease. Mov Disord. 2014;29(8):967-975.
• Kano O, Ikeda K, Cridebring D, Takazawa T, Yoshii Y, Iwasaki Y. Neurobiology of Depression and Anxiety in Parkinson's Disease. Parkinson’s Dis. 2011;2011:143547.
• Mathew SJ, Coplan JD, Gorman JM. Neurobiological Mechanisms of Social Anxiety Disorder. J Psychiatry. 2001;158(10):1558-1567.
• Nilsson, FM, Kessing LV, Bolwig TG. Increased risk of developing Parkinson's disease for patients with major affective disorder: a register study. Acta Psychiatrica Scandinavica 104.5(2001):380-386.
• Ovallath S, Sulthana B. Levodopa: History and Therapeutic Applications. Ann Indian Acad Neurol. 2017;20(3):185-189.
• Eskow Jaunarajs KL, Dupre KB, Ostock CY, Button T, Deak T, Bishop C. Behavioral and neurochemical effects of chronic L-DOPA treatment on nonmotor sequelae in the hemiparkinsonian rat. Behav Pharmacol. 2010;21(7):627-637.
• Arango V, Underwood MD, Boldrini M, Tamir H, Kassir SA, Hsiung S, et al. Serotonin 1A receptors, serotonin transporter binding and serotonin transporter mRNA expression in the brainstem of depressed suicide victims. Neuropsychopharmacology. 2001 Dec;25(6):892-903. doi: 10.1016/S0893-133X(01)00310-4. PMID: 11750182.
• Lemonde S, Turecki G, Bakish D, Du L, Hrdina PD, Bown CD, et al. Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J Neurosci. 2003 Sep 24;23(25):8788-99. doi: 10.1523/JNEUROSCI.23-25-08788.2003. PMID: 14507979; PMCID: PMC6740417.
• Schrag A, Politis M. Serotonergic loss underlying apathy in Parkinson’s disease. Brain J. Neurol., 139 (Pt 9) 2016; 2338-2339 Garcia-Garcia AL, Newman-Tancredi A, Leonardo ED. P5-HT 1A receptors in mood and anxiety: recent insights into autoreceptor versus heteroreceptor function. Psychopharmacology, 2014;231(4):623-636
• L. Díaz-Mataix, M.C. Scorza, A. Bortolozzi, M. Toth, P. Celada, F. Artigas. Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J. Neurosci., 25 (47) 2005; 10831-10843.
• Bokor G, PD Anderson. Obsessive–compulsive disorder. Journal of pharmacy practice, 2014. 27(2):116-130.
• Pittenger C, Bloch MH. Pharmacological treatment of obsessivecompulsive disorder. Psychiatric Clinics, 2014;37(3):375-391.
• Benzina N, Mallet L, Burguière E, N'Diaye K, Pelissolo A. Cognitive Dysfunction in Obsessive-Compulsive Disorder. Curr Psychiatry Rep. 2016;18(9):80.
• Veale D, Roberts A. Obsessive-compulsive disorder. Br Med J. 2014;348:1–6.
• Calne D. A definition of Parkinson's disease. Parkinsonism Relat Disord 2005;11:39-40ç
• Alegret M, Junqué C, Valldeoriola F, Vendrell P, Martí MJ, Tolosa E, et al. Obsessive-compulsive symptoms in Parkinson's disease. J Neurol Neurosurg Psychiatry 2001, 70(3):394–396. Tomer R, Levin B, Weiner W. Obsessive-compulsive symptoms and motor asymmetries in Parkinson's disease. Neuropsychiatry Neuropsychol Behav Neurol 1993; 6:26–30.
• Antonini A, Barone P, Bonuccelli U, Annoni K, Asgharnejad M, Stanzione P. ICARUS study: Prevalence and clinical features of impulse control disorders in Parkinson's disease. J Neurol Neurosurg Psychiatry 2017;88:317-324.
• Maréchal E, Denoiseux B, Thys E, Crosiers D, Pickut B, Cras P. Impulse control disorders in Parkinson's disease: An overview from neurobiology to treatment. J Neurol 2015;262:7-20.
• Cardinal RN, Parkinson JA, Hall J, Everitt BJ. Emotion and motivation: the role of the amygdala, ventral striatum, and prefrontal cortex. Neurosci. Biobehav. Rev. 2002:321–352.
• Latella D, Maggio MG, Maresca G, Saporoso AF, Le Cause M, Manuli A, et al. Impulse control disorders in Parkinson's disease: A systematic review on risk factors and pathophysiology. J Neurol Sci. 2019;398:101-106.
• Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67(5):589-595.
• Inanc Y, Kaya T. Psychiatric Disorders in Multiple Sclerosis. J Mult Scler Res. 2022; 2(2): 31-35.
• Kaya T, Aktan EA, Turgut C. The Relationship of Childhood Traumatic Experiences, Dissociative Symptoms and Emotion Regulation in Patients with Bipolar Mood Disorder. Yüksek Lisans Tezi. Nişantaşı Üniversitesi Lisansüstü Eğitim Enstitüsü Psikoloji Anabilim Dalı 2022 İstanbul.
• Fénelon G, Soulas T, Zenasni F, De Langavant LC. The changing face of Parkinson’s disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria. Mov Disord. 2010;25(6):755–759.
• Stahl SM. Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: dopamine, serotonin, and glutamate. CNS Spectr. 2018;23(3):187-191
• Eggers AE. A serotonin hypothesis of schizophrenia. Medical Hypotheses. 2013 Jun;80(6):791–794.
• Studerus E, Kometer M, Hasler F, Vollenweider FX. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol. 2011;25(11):1434–1452.